Healthcare
Live Price
Offline$189.90
-1.35% today
Window Change
+42.83%
Window
Jun 23, 2025 → Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars · Jun 23, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AstraZeneca PLC (AZNCF) is a Healthcare stock with a market cap of $294.40B. The stock last traded around $189.90 and up 42.8% across the available one-year price window (Jun 23, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of +45.4%, a dividend yield of 1.8%. What stands out right now is revenue +8.6%, EPS +45.4%, free cash flow +19.2% with operating margin 23.5% and ROIC 12.9%. The dividend is present but secondary, with a yield around 1.8%. Valuation sits in the middle of the pack at P/E 26.9 and price/sales 4.6. Stock Foundry combines AZNCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AZNCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AZNCF Max Drawdown
-12.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AZNCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$37.4B
-15.6% YoY
FY Net Income
$112.0M
-96.6% YoY
Free Cash Flow
$3.8B
-48.0% YoY
Revenue Growth
+8.6%
EPS Growth
+45.4%
Gross Margin
79.7%
Net Margin
17.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 58.7B | 54.1B | 45.8B | 44.4B | 37.4B |
| Gross Profit | 48.1B | 43.9B | 37.5B | 32.0B | 25.0B |
| Operating Income | 13.7B | 10.0B | 8.2B | 3.8B | 1.1B |
| EBITDA | 19.8B | 15.4B | 13.9B | 9.0B | 5.0B |
| Net Income | 10.2B | 7.0B | 6.0B | 3.3B | 112M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.7B | 5.5B | 5.8B | 6.2B | 6.3B |
| Total Assets | 114.1B | 104.0B | 101.1B | 96.5B | 105.4B |
| Total Liabilities | 65.4B | 63.2B | 62.0B | 59.4B | 66.1B |
| Shareholder Equity | 48.7B | 40.8B | 39.1B | 37.0B | 39.3B |
| Total Debt | 29.6B | 30.1B | 28.6B | 29.2B | 30.8B |
| Net Debt | 23.9B | 24.6B | 22.8B | 23.1B | 24.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6.0B
-39.2% YoY
Capital Expenditures
2.2B
+14.4% YoY
Free Cash Flow
3.8B
-48.0% YoY
Key ratios
Gross Margin
79.7%
Operating Margin
23.5%
Net Margin
17.2%
ROE
22.4%
Debt / Equity
0.72x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.